This article has been updated with comments and information from Twist's earnings call.
NEW YORK – Twist Bioscience on Friday again raised its fiscal year 2024 revenue guidance following record revenues in its fiscal third quarter.
The firm now expects revenues between $310 million and $311 million for the year, up from a previous range of $300 million to $304 million.
For the three months ended June 30, Twist reported $81.5 million in revenues, up from $63.7 million in the prior-year period, beating its previous guidance and Wall Street analysts' average estimate of $77.4 million.
"The strong quarter was driven by growth in synthetic biology … along with robust growth in NGS," CEO and Cofounder Emily Leproust said on a conference call with investors following the release of the results. She noted that the firm exceeded its targets for both cash burn rate and gross margin.
Synthetic biology revenues were $33.0 million, including oligo pools revenues of $4.2 million and DNA libraries revenues of $3.8 million. Next-generation sequencing revenues were $43.4 million, and biopharma revenues were $5.2 million.
By industry, healthcare revenues were $42.8 million, up 26 percent year over year; industrial chemical revenues were $23.2 million, up 38 percent; and academic revenues were $14.9 million, up 20 percent. By geography, revenues from the Americas were $51.4 million, up 32 percent year over year; revenues from Europe, the Middle East, and Africa were $23.6 million, up 24 percent; and revenues from Asia Pacific were $6.5 million, up 15 percent. In particular, revenues from China were $1.8 million.
Twist shipped approximately 212,000 genes during the quarter, up from 171,000 a year ago.
The firm's net loss for the quarter was $85.6 million, or $1.47 per share, compared to a net loss of $57.4 million, or $1.01 per share, in the year-ago quarter, missing the consensus Wall Street estimate of a loss of $.76 per share.
During the quarter, Twist took a $44.9 million non-cash impairment related to biopharma assets. "We revisited our long-term growth forecast for biopharma, and we believe the outlook shifted from our original view," Twist CFO Adam Laponis said. Excluding the impairment, adjusted net loss was $40.6 million.
Twist's research and development expenses for the quarter fell 8 percent to $22.5 million from $24.5 million in fiscal Q3 2023. Selling, general, and administrative expenses totaled $56.8 million, up 23 percent from $46.1 million a year ago.
The company ended the quarter with $239.2 million in cash and cash equivalents and $50.3 million in short-term investments.
For fiscal Q4, Twist expects $82 million to $83 million in revenues compared to a previous estimate of $77 million to $80 million.
In Friday morning trading on the Nasdaq, shares of Twist were down 11 percent at $47.09.